This work is licensed under a Figure 2.
TβR1 knockout in mouse BRAFV600E-PTCs is insufficient to inhibit SMAD activation in vivo. (A) Schematic design of the transgenic lines used in this study and of their recombination when crossed with TPO-Cre mice: (1) Lsl-BrafV600E; (2) TβR1f/f and (3) tetO-shTβR1/RIK. (B) β-actin normalized expression of TβR1 mRNA in thyroid tissues of the indicated mouse lines as determined by quantitative RT-PCR (n = 4/group). *P < 0.05, **P < 0.005, ns = not significant. (C) Western blots for pSMAD and pERK in lysates from normal thyroid or PTCs from Braf, Braf/TβR1 and Braf/shTβR1 mice. (D) Western blots of cell lines derived from PTCs of Braf, Braf/TβR1, and Braf/shTβR1 mice treated with vehicle or 1 ng/mL TGFβ1 for 1 h. Cells treated with dox were incubated for 3 days prior to collection.